Very recently, a de Novo ESR1 Hotspot Mutation was detected in a patient with endometrial cancer treated with an aromatase inhibitor [49], while it has been reported that—in endometrial cancer—ESR1 mutations are associated with worse outcomes and less obesity [50]. Here, ESR1 is linked to endometrial cancer.